Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
A-Z
> Cell and Gene Therapy - Bridging Academia with Industry
Guest Speakers:
Yoh-ichi Tagawa, D.Sc.
Associate Professor
School of Life Science and Technology, Tokyo Institute of Technology
Topic:
Mimic the human intestinal environment by using a microfluidic device to co-culture intestinal epithelium and microorganisms
Dr. Steven A. Feldman, Ph.D.
Site Head/Scientific Director
Stanford Laboratory of Cell and Gene Medicine & Stanford Center for Cancer Cell Therapy
Topic:
Development of a Non-viral Gene Delivery Platform for CAR T Manufacturing
Introduction:
Innovations in cell and gene therapy require the development of novel technologies and applications, such as genome editing and CAR-T cells for immunotherapy, which start in academia. However, to realize their potential for clinical translation, there are important considerations for successful process development. Join our workshop to learn about the latest advancements in cell and gene therapy, including GMP reagents, organoids as disease models, and clinical scale CAR-T cell manufacturing by non-viral methods. Our workshop, co-hosted with MaxCyte, will be taking place on July 19th, 2024 (10:00 AM - 1:00 PM) at Shirankaikan Annex（芝蘭会館別館）at Kyoto University.
Learning Objectives:
- Discover the latest advancements in cell and gene therapy, from discovery to the clinic.
- Learn about cell and gene therapies from different industry perspectives.
- Network with Leading CGT Researchers and Industry Experts!
Food and drinks will be served for in-person attendees
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
MaxCyte® stands at the forefront of cell-engineering, providing the leading transfection platform powered by our Flow Electroporation® technology, that is instrumental in the discovery and commercialization of cutting-edge cell-based therapies. In 2024, our ExPERT™ electroporation platform is the only proven transfection technology supporting a commercialized non-viral cell therapy. Coupled with our unparalleled scientific, technical and regulatory support, we enable the complex engineering required for the creation of innovative cell therapies. As a trailblazer in this field for 25 years, we are committed to transforming the future of medicine and helping improve patient outcomes. Let MaxCyte be your partner in navigating the exciting landscape of cell therapy development.
This web search service is supported by Google Inc.
